Auriga Reiterates a 'Buy' on Impax Laboratories (IPXL); Positive After Meetin with Management
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Price: $18.30 --0%
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Impax Laboratories (NASDAQ: IPXL) price target of $30.00.
Analyst, Louise Chen, said, "We are reiterating our rating and price target for IPXL shares post our meeting with Carole Ben-Maimon, President of Global Pharmaceuticals and Mark Donohue, IR on 5/9/12. Our meeting with management underscores our investment thesis for IPXL shares which is that 2013 earnings potential is underappreciated. In 2013, we could look forward to: 1) Additional new, accretive acquisition(s) to be in place (prefer brand with alternate dosage form, injectable, patches, nasals and implants); 2) Launch of IPX066 for Parkinson's; 3) Margin expansion and a lower tax rate driven by Taiwan manufacturing (several hundred bps); 4) New generic launches; 5) Positive Phase IIb data for IPX159, for Restless Leg Syndrome; 6) OUS expansion of generics business; 7) Settlement with Shire for generic Adderall XR that could extend agreement beyond 9/2014; and 8) Launch of generic Opana ER 1/1/13 with downside protection from Endo (Nasdaq: ENDP)."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $22.00 yesterday.
Analyst, Louise Chen, said, "We are reiterating our rating and price target for IPXL shares post our meeting with Carole Ben-Maimon, President of Global Pharmaceuticals and Mark Donohue, IR on 5/9/12. Our meeting with management underscores our investment thesis for IPXL shares which is that 2013 earnings potential is underappreciated. In 2013, we could look forward to: 1) Additional new, accretive acquisition(s) to be in place (prefer brand with alternate dosage form, injectable, patches, nasals and implants); 2) Launch of IPX066 for Parkinson's; 3) Margin expansion and a lower tax rate driven by Taiwan manufacturing (several hundred bps); 4) New generic launches; 5) Positive Phase IIb data for IPX159, for Restless Leg Syndrome; 6) OUS expansion of generics business; 7) Settlement with Shire for generic Adderall XR that could extend agreement beyond 9/2014; and 8) Launch of generic Opana ER 1/1/13 with downside protection from Endo (Nasdaq: ENDP)."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $22.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Movano (MOVE) Misses Q2 EPS by 195c
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Auriga, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
